PMEF
DNLI icon

Point72 Middle East FZE’s Denali Therapeutics DNLI Stock Holding History

Point72 Middle East FZE’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,549
Closed -$1.05M – 1539
2023
Q2 		$1.05M Buy
35,549
+24,701
+228% +$695K 0.03% 580
2023
Q1 		$250K Buy
10,848
+7,255
+202% +$200K 0.01% 878
2022
Q4 		$99.9K Buy
+3,593
New +$107K ﹤0.01% 1275

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Point72 Middle East FZE's DNLI Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 35,549 shares — an estimated $1.05M sold.

Point72 Middle East FZE first reported a position in DNLI in Q4 2022 and held it in 3 quarters. The position peaked at $1.05M in Q2 2023. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 35,549 Denali Therapeutics shares in Q3 2023, an estimated $1.05M.
  • Point72 Middle East FZE first reported a position in Denali Therapeutics in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Denali Therapeutics position peaked at $1.05M in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.